ANG Lifesciences India share news, announcements and annual reports
BSE: 540694Pharmaceuticals & BiotechnologySmall Cap
Share price at the BSE close on 2 Nov 2026. Previous close ₹32.09.
2 Nov: open ₹32.09, high ₹34.50, low ₹31.00
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹43 Cr3,715th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- Lossover the last 12 months
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 0.81
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- −22.8%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- −6.3%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 1.47
- Volume, BSEVolume. Shares traded on the last trading day. Volume in the glossary
- 2,769
ANG Lifesciences India share news and announcements
374 announcements, routine notices left out, newest first. Page 3 of 8.
Aug 2023
7 Aug · Board meeting
Meeting on 14 Aug 2023: quarterly results
Jun 2023
1 Jun · Certificate Under Regulation 40(9) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015.
May 2023
30 May · Announcement under Regulation 30 (LODR)-Meeting Updates
23 May · Board meeting
Meeting on 30 May 2023: audited results3 May · Meeting
Apr 2023
5 Apr · Board meeting
Mar 2023
28 Mar · Announcement under Regulation 30 (LODR)-Meeting Updates
Feb 2023
27 Feb · Board meeting
Meeting on 6 Mar 2023: increase in authorised capital and preferential issue of shares14 Feb · Board meeting
6 Feb · Board meeting
Meeting on 14 Feb 2023: quarterly results
Jan 2023
30 Jan · Announcement under Regulation 30 (LODR)-Meeting Updates
Dec 2022
Nov 2022
25 Nov · Disclosure Of Related Party Transactions For The Half Year Ended 30Th September, 2022.
14 Nov · Results
11 Nov · Meeting
7 Nov · Board meeting
Meeting on 14 Nov 2022: quarterly results
Oct 2022
17 Oct · Board meeting
12 Oct · Statement Of Investor Complaints For The Quarter Ended September 2022
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0 0 0 010 Oct · Board meeting
Meeting on 17 Oct 2022: preferential issue of shares1 Oct · Meeting
Sep 2022
7 Sep · Reg. 34 (1) Annual Report.
5 Sep · Results
Aug 2022
29 Aug · Board meeting
Meeting on 5 Sep 2022: annual general meeting